Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 17/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 13/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7772954 | 0.91 | PTGS2 (0.56) | PTGS2PTGS1MEN1KMT2ABRAF | |
| SCHEMBL7778116 | 0.87 | PTGS2 (0.49) | PTGS2PTGS1CA2CA1CA9 | |
| SCHEMBL7780516 | 0.87 | PTGS2 (0.59) | PTGS2PTGS1MEN1KMT2A | |
| SCHEMBL7772854 | 0.87 | PTGS2 (0.45) | PTGS2PTGS1BRAFMAPK3MAPK1 | |
| SCHEMBL8635525 | 0.86 | ALOX5AP (0.43) | PTGS2 | |
| SCHEMBL7779469 | 0.86 | PTGS2 (0.56) | PTGS2PTGS1MEN1KMT2ACA2 | |
| SCHEMBL7777564 | 0.86 | CA9 (0.49) | PTGS2PTGS1MEN1KMT2ACA2 | |
| SCHEMBL7779464 | 0.85 | PTGS2 (0.46) | PTGS2PTGS1CA2CA1CA9 | |
| SCHEMBL7773097 | 0.84 | PTGS2 (0.46) | PTGS2PTGS1CA2CA1 | |
| SCHEMBL7778042 | 0.83 | PTGS2 (0.52) | PTGS2PTGS1CA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0772597-B1 | 3,4-SUBSTITUTED PYRAZOLES FOR THE TREATMENT OF INFLAMMATION | SEARLE & CO (US) | 2001-12-12 | — | — | EP | disclosed |
| EP-1127878-A1 | 3,4 - substituted pyrazoles for the treatment of inflammation | G.D. SEARLE & CO. (US) | 2001-08-29 | — | — | EP | disclosed |
| US-6028072-A | 3,4-substituted pyrazoles for the treatment of inflammation | G. D. SEARLE & CO. (US) | 2000-02-22 | — | — | US | disclosed |
| EP-0772597-A1 | 3,4-SUBSTITUTED PYRAZOLES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1997-05-14 | — | — | EP | disclosed |
| US-5580985-A | ANTIARTHRITIC AGENT; SIDE EFFECT REDUCTION | G. D. SEARLE & CO. (US) | 1996-12-03 | — | — | US | disclosed |
| WO-1996003385-A1 | 3,4-SUBSTITUTED PYRAZOLES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-02-08 | — | — | WO | disclosed |
| US-5486534-A | 3,4-substituted pyrazoles for the treatment of inflammation | G. D. SEARLE & CO. (US) | 1996-01-23 | — | — | US | disclosed |